Search

Amlodipine, a novel dihydropyridine calcium-antagonist, was compared to slow-release nifedipine in a short-term study on 40 patients with mild to moderate essential hypertension, in order to assess the efficacy and tolerability of two different dihydropyridine calcium-antagonists with short and long half-life. After a two-week single-blind placebo period, patients were given, in a randomized sequence, amlodipine (5 or 10 mg/day od, 20 patients) or nifedipine s.r. (20 or 40 mg BID, 20 patients). At the end of treatment (12 weeks) a significant lowering of arterial pressure was obtained after 24h from the administration of amlodipin (-34/-17 mmHg) and after 12h from the administration of nifedipine s.r. (-33/-16 mmHg). Furthermore, with both drugs, no significant changes in heart rate and ECG have been reported. Amlodipine was better tolerated than nifedipine, as shown by the lower incidence of side effects. Therefore amlodipine proved to be an effective and well tolerated drug in the therapy of mild to moderate hypertension.

Patients with symptomatic myocardial ischaemia received amlodipine (once daily) or diltiazem (three times daily) for 10 weeks. Amlodipine and diltiazem showed comparable efficacy in reducing angina attack rates and glyceryl trinitrate consumption. Amlodipine produced a significantly greater reduction in the mean rate pressure product. Both drugs were well tolerated with only mild side effects occurring at the higher doses. In two cases, side effects were also reported at the lower dose of diltiazem (30 mg three times daily); none occurred with the 5-mg daily dose of amlodipine. In the overall clinical assessment, efficacy of amlodipine was considered excellent in 100% of cases as compared with 40% for diltiazem. Amlodipine is clearly effective when administered once daily for the treatment of myocardial ischaemia.

Forty patients with mild-to-moderate arterial hypertension were randomized for double-blind treatment with ketanserin (20 mg b.i.d.) vs. captopril (25 mg b.i.d.) for fifteen days. Diastolic pressure was normalized (less than 90 mmHg) in 11 out of 20 patients of both groups. Of the 18 patients not responding to monotherapy, 17 were treated for 45 days with a combination of both drugs at the same dosages. Diastolic blood pressure was normalized in 15 out of these 17, and in one patient it was reduced by more than 10%. Thus the success rate of therapy was 94%.

A group of 30 patients with II-III NYHA class cardiac insufficiency was treated with ibopamine in association with other drugs for a 6-month period. The patients were submitted to a 24-h ambulatory ECG Holter monitoring, chest X-ray, Doppler echocardiography in order to calculate total peripheral vascular resistance. Blood levels of aldosterone and renin-angiotensin activity in plasma were also measured, together with norepinephrine excretion. The measurements and recordings were performed in basal conditions before the trial, and were repeated after the first, second, third and sixth month. Laboratory tests were performed at the baseline and after 6 months. The results showed a significant decline in the number of ventricular and supraventricular ectopic beats after treatment. Heart rate did not change. Cardio-thoracic ratio decreased significantly along with peripheral vascular resistance. A very noticeable decline in all three neurohormonal parameters, i.e. norepinephrine excretion, blood level of aldosterone and renin activity in plasma was observed after 1 month's treatment, and this reduction was still present without any attenuation after 6 months. No significant changes were observed in routine laboratory tests.

Sixteen angina patients were submitted to echocardiographic examination during the cold pressor test and during hand grip. Certain left ventricular function echocardiographic parameters were assessed in these subjects and in a further 14 patients presenting negative histories for cardiovascular diseases who represented the control group. Of the two tests associated with echocardiography, the cold pressor test appeared capable of inducing the more evident changes on left ventricular function compared to isometric effort in subjects suffering from ischaemic cardiopathy.

The discovery tha carnitine takes an active part in the transportation of long-chain acyl residues across the inner mitochondrial membrane dates back to 1958. It has been shown experimentally tha a reduction in myocardial carnitine content takes place after 15-30 min of ischemia. L-carnitine was administered orally in doses of 3 g/day for 30 days to 16 subjects with effort-induced angina and to 14 healthy subjects. A bicycle ergometer exercise test revealed a 1.5 mm (mean) depression of the ST-T segment in the angina subjects after pharmacological wash-out and a 1 mm depression in the same subjects after carnitine treatment. M-code echocardiography showed positive changes in a number of ventricular function parameters in the angina subjects and also, to a lesser extent, in the healthy controls.